These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Mahesh R; Perumal RV; Pandi PV Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895 [TBL] [Abstract][Full Text] [Related]
5. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. Oo TH; Hesketh PJ Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934 [TBL] [Abstract][Full Text] [Related]
6. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Herrstedt J Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151 [TBL] [Abstract][Full Text] [Related]
7. Aprepitant (EMEND): the role of substance P in nausea and vomiting. Prommer E J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609 [TBL] [Abstract][Full Text] [Related]
8. Emerging treatments in chemotherapy-induced nausea and vomiting. Grunberg SM; Slusher B; Rugo HS Clin Adv Hematol Oncol; 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819 [TBL] [Abstract][Full Text] [Related]
9. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. Slatkin NE J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383 [TBL] [Abstract][Full Text] [Related]
10. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Hsu ES Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345 [TBL] [Abstract][Full Text] [Related]
11. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development. Rizk AN; Hesketh PJ Drugs R D; 1999 Oct; 2(4):229-35. PubMed ID: 10659396 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Schwartzberg LS Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696 [TBL] [Abstract][Full Text] [Related]
13. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study. Tan M; Xu R; Seth R Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746 [TBL] [Abstract][Full Text] [Related]
14. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Rubenstein EB; Slusher BS; Rojas C; Navari RM Cancer J; 2006; 12(5):341-7. PubMed ID: 17034670 [TBL] [Abstract][Full Text] [Related]
15. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Hesketh PJ Support Care Cancer; 2001 Jul; 9(5):350-4. PubMed ID: 11497388 [TBL] [Abstract][Full Text] [Related]
16. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Chu CC; Hsing CH; Shieh JP; Chien CC; Ho CM; Wang JJ Eur J Pharmacol; 2014 Jan; 722():48-54. PubMed ID: 24184695 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced nausea and vomiting. Lohr L Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612 [TBL] [Abstract][Full Text] [Related]
18. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Navari RM Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308 [TBL] [Abstract][Full Text] [Related]
19. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106 [TBL] [Abstract][Full Text] [Related]
20. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Cunningham RS Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]